Assessment of effect of levamisole on pneumonia caused by COVID-19

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20131215015805N2

Enrollment

Registered

2020-05-04

Start date

2020-05-04

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus infection. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: Intervention group: 50 mg three times daily for levamisole for 5 days. Intervention 2: Control group: Like levamisole, placebo will be given three times a day.

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: COVID-19 Patients moderate Lung Complication informed consent

Exclusion criteria

Exclusion criteria: Patients with WBC COUNT <6000 Platelet less than 100 thousand Patients with immune diseases Previous respiratory diseases Cancer Pregnancy Breast Feeding immunosuppressive medication organ transplant autoimmune disease

Design outcomes

Primary

Measure	Time frame
Prevent the development of pneumonia caused by Convid19. Timepoint: one week. Method of measurement: CT scan.;Reduce the need for hospitalization. Timepoint: two week. Method of measurement: Measure the length of hospital stay.;Death. Timepoint: 2 to 3 week. Method of measurement: Measuring mortality.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Payam Peymani

Shiraz University of Medical Sciences

peymani.payam@gmail.com+98 71 3230 9615

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026